middle.news
Invion Advances Cancer Trials with Key Milestones and New Funding
9:52am on Friday 31st of January, 2025 AEDT
•
Life Sciences
Read Story
Invion Advances Cancer Trials with Key Milestones and New Funding
9:52am on Friday 31st of January, 2025 AEDT
Key Points
First patient dosed in Phase I/II non-melanoma skin cancer trial
Promising safety and efficacy signals from Phase II prostate cancer trial
Strategic partnerships advancing in South Korea with Hanlim Pharm and Dr.inB
Appointment of Prof Rob Ramsay as Scientific Advisor
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
Invion (ASX:IVX)
OPEN ARTICLE